109 related articles for article (PubMed ID: 22260162)
1. Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan.
Chen SH; Yang CP; Jaing TH; Hung IJ; Shih LY; Ho PC; Lee WI; Huang JL
Leuk Lymphoma; 2012 Aug; 53(8):1536-42. PubMed ID: 22260162
[TBL] [Abstract][Full Text] [Related]
2. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
3. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
4. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
Pieters R; Huismans DR; Loonen AH; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
Lancet; 1991 Aug; 338(8764):399-403. PubMed ID: 1678081
[TBL] [Abstract][Full Text] [Related]
5. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
7. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
9. Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Jun KR; Jang S; Chi HS; Lee KH; Lee JH; Choi SJ; Seo JJ; Moon HN; Im HJ; Park CJ
Korean J Lab Med; 2007 Apr; 27(2):89-95. PubMed ID: 18094557
[TBL] [Abstract][Full Text] [Related]
10. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
11. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
12. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.
Pieters R; Loonen AH; Huismans DR; Broekema GJ; Dirven MW; Heyenbrok MW; Hählen K; Veerman AJ
Blood; 1990 Dec; 76(11):2327-36. PubMed ID: 2257305
[TBL] [Abstract][Full Text] [Related]
14. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
16. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia.
Holleman A; den Boer ML; Kazemier KM; Janka-Schaub GE; Pieters R
Blood; 2003 Dec; 102(13):4541-6. PubMed ID: 12920041
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
18. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
[TBL] [Abstract][Full Text] [Related]
20. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
